Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
congenital adrenal hyperplasia
Pharma
FDA approves Neurocrine's Crenessity for genetic adrenal disease
After seven decades with no advances in the treatment of congenital adrenal hyperplasia, Neurocrine has scored an FDA approval for Crenessity.
Kevin Dunleavy
Dec 16, 2024 11:26am
Neurocrine asks ‘What the C@H?!’ in new hyperplasia campaign
Apr 25, 2024 12:04pm